clinical trial · NCT07487948
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Icahn School of Medicine at Mount Sinai·phase2·recruiting·n = 30
Central Centrifugal Cicatricial AlopeciaLichen PlanopilarisDelgocitinib
brief summary
This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).
started
May 19, 2026
primary completion
Apr 5, 2027
completion
Dec 31, 2027
last updated
Jun 4, 2026
official title
A Pilot Study to Assess Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol